With the advent of small-molecule drugs,treatment of inflammatory bowel disease(IBD)has reached a new stage.In contrast to biologics,small-molecule drugs can be made into oral dosage forms with a short half-life and are suitable for administration 1–2 times a day.Small-molecule drugs work by inhibiting the transmission of key intracellular signaling pathways in the pathogenesis of ulcerative colitis(UC)and Crohn’s disease(CD)[Figure 1].They do not induce anti-drug antibodies in patients or lead to loss of response after treatment.
Dongying Yao;Zhihua Ran;
Department of Gastroenterology,Zhou Pu Hospital affiliated to Shanghai University of Health&Medical Sciences,Shanghai 201318,China
临床医学
drugs;treatment;inflammatory;
《Chinese Medical Journal》 2024 (005)
P.556-558 / 3
10.1097/CM9.0000000000003026
评论